



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	384639	Ther-Biotic BioDaily
ARTG entry for	Medicine Listed	
Sponsor	SFI Australasia	
Postal Address	Level 2 / 170 Pacific Highway, St. Leonards, NSW, 2065 Australia	
ARTG Start Date	24/02/2022	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . THER-BIOTIC BioDaily

Product Type	Single Medicine Product	Effective Date	17/06/2022
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Maintain/support bowel regularity
Decrease/reduce/relieve bowel discomfort
Helps reduce occurrence of symptoms of traveller's diarrhoea
Maintain/support healthy bowel/colon function
Maintain/support intestinal health
Maintain/support healthy digestive system function
Maintain/support intestinal good/beneficial/friendly flora
Maintain/support intestinal good/beneficial/friendly flora in elderly individuals
Helps maintain/support good/beneficial/friendly gut flora during antibiotic use
Helps restore good/beneficial/friendly intestinal/gut/bowel flora
Maintain/support gastrointestinal system health
Maintain/support healthy gastrointestinal function
Decrease/reduce/relieve abdominal bloating/distention
Maintain/support healthy immune system function

Indication Requirements

Product presentation must not imply or refer to gastro oesophageal reflux disease.
Label statement: If symptoms persist, talk to your health professional.

Label statement for stimulant laxatives: Prolonged use may cause serious bowel problems.
Label statement: Do not use when abdominal pain, nausea or vomiting are present or if you develop diarrhoea. If you are pregnant or breastfeeding - seek the advice of a healthcare professional before taking this product (or words to that effect).

Product presentation must not refer to or imply weight loss.
Label statement: Drink plenty of water (or words to that effect).

Label statement: Seek medical advice if diarrhoea persists for more than: 6 hours in infants under 6 months, 12 hours in children under 3 years, 24 hours in children aged 3 to 6 years or 48 hours in adults and children over 6 years (or words to that effect).

Product presentation must not imply or refer to serious immunological diseases.

Standard Indications



Australian Government
Department of Health
Therapeutic Goods Administration

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

No Warnings included on Record

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Capsule, hard

Route of Administration Oral

Visual Identification

Active Ingredients

Bifidobacterium animalis ssp lactis	2 billion CFU
Bifidobacterium animalis ssp lactis	2.5 billion CFU
Bifidobacterium breve	2.5 billion CFU
Bifidobacterium lactis	2 billion CFU
Lactobacillus plantarum	2.5 billion CFU
Saccharomyces cerevisiae (Boulardii)	10 billion CFU

Other Ingredients (Excipients)

colloidal anhydrous silica

hypromellose

magnesium stearate

microcrystalline cellulose

sorbitan monolaurate

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary